The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The History of Treating Lupus with Hydroxychloroquine

The History of Treating Lupus with Hydroxychloroquine

June 15, 2020 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Dr. Esdaile

Dr. Esdaile

Dr. Esdaile, who trained nearby at Yale University, spoke to Dr. Rothfield in detail about the work. He coordinated the study out of Montreal General Hospital, Quebec, Canada, where he was working at the time. He recruited doctors from two other hospitals in Montreal, from a hospital in Ottawa and from another in Hamilton, Ontario. Those physicians then asked their colleagues to send them any lupus patients who were doing well and currently taking hydroxychloroquine.

You Might Also Like
  • New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine
  • Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?
  • Diagnostic Imaging in Lupus Patient with Foot Pain: History
Explore This Issue
June 2020
Also By This Author
  • ACR Convergence 2020: Progress Toward COVID-19 Vaccines

“The fact that the Canadians banded together to do this is a remarkable substory of this paper,” says Dr. Petri. “They are lumped together as the Canadian Hydroxychloroquine Study Group. This is a great example of clinicians caring about lupus and not caring about their own names or their own egos.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Study Design & Outcomes

Dr. Esdaile and colleagues opted to perform a prospective, double-blind, randomized withdrawal study to examine the potential protective role of hydroxy­chloroquine in preventing disease flares.

The group studied lupus patients who had been taking hydroxychloroquine in doses ranging from 100 mg to 400 mg per day. The average length of time the lupus patients had been taking hydroxy­chloroquine was three years, and all patients had taken it for at least six months. All had experienced clinical remission or only minimal disease activity for the three months prior to study initiation. The patients were randomized to either continue taking hydroxychloroquine at their current dose or to take a placebo.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Esdaile explains the characteristics of lupus make it challenging to study. He partly chose the withdrawal design because lupus often requires intensive intervention with stronger drugs, such as prednisone for flares of disease activity. He believed the effect of that would obscure the impact of hydroxychloroquine, making benefits harder to see.

In 2016, the American Academy of Ophthalmology published guidelines for hydroxychloroquine patient monitoring, recommending optical coherence tomogram at baseline, five years thereafter & then every year following for patients without major risk factors for retinopathy. … In terms of toxicity, recent guidelines … recommend lowering the dosage from 6.5 mg/kg patient weight to less than 5.0 mg/kg.

“If you used people who had never seen hydroxychloroquine, the flare would create a nightmare for analysis,” he says. “Whereas the way we designed it, the flareup was the outcome.” Additionally, because many doctors and patients had concerns about taking the drug continuously, Dr. Esdaile says it would have been more difficult to find patients to enroll in a trial of patients naive to hydroxychloroquine.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Blinding the study properly was a challenge, because hydroxychloroquine formulations at the time had a strong, unpleasant taste. Dr. Esdaile worked with the drug manufacturer to obtain a drug and a placebo in identical shapes. To help with the disguise, the placebos were coated with a trace amount of hydroxychloroquine (<1 mg), so they would also have an unpleasant taste.

The group assessed patients every four weeks over a 24-week period using standard clinical assessments and laboratory tests. Final analyses included 47 patients with lupus.1 Using data from Dr. Rothfield’s work, Dr. Esdaile and colleagues estimated that staying on hydroxychloroquine would reduce flares by about 50% with their study design.

Dr. Esdaile and colleagues found the relative risk of a clinical flare-up (the primary outcome) was 2.5 times higher in patients taking placebo than in those who had continued to take hydroxychloroquine. Moreover, the relative risk of the secondary outcome, severe disease exacerbation, was six times higher in patients taking placebo than in those who had continued taking hydroxychloroquine. (This, however, did not reach statistical significance, which was unsurprising given study size and length.)

The findings also provided early evidence that hydroxychloroquine treatment might reduce nephritic flares successfully. Efforts to properly blind the study were successful, with only 53% of participants correctly guessing whether they were taking hydroxychloroquine or placebo.1

“It was a remarkably simple study, and the preventive role of hydroxychloroquine was so strong,” Dr Petri remarks. She contrasts the sample size with those found in modern studies using much higher numbers of patients. She adds, “I often say if something really works, you don’t need a lot of patients to show it. And that’s one reason why I think this is such a wonderful study.”

The randomized withdrawal trial design is now only rarely used in lupus, although it is still sometimes employed in juvenile chronic arthritis studies. Dr. Petri says, “I think this shows that maybe we’ve forgotten it’s a good study design.”

Randomized withdrawal trials do present problems of generalizability. For example, such a trial design excludes patients who had previously discontinued hydroxychloroquine due to lack of response, toxicity or other factors, and thus may tend to overestimate efficacy.

But Dr. Esdaile emphasizes that one of the design’s strengths is the ability to show an effect with a smaller sample size.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Lost & Found, retinopathy, SLE Resource CenterIssue: June 2020

You Might Also Like:
  • New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine
  • Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?
  • Diagnostic Imaging in Lupus Patient with Foot Pain: History
  • Reflections on Living with Lupus, and on Treating It

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)